Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Elie Rassy, Cécile Dalban, Émeline Colomba, Lisa Derosa, Carolina Alves Costa Silva, Sylvie Négrier, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, M. Gross Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Laurence Albigès
Topics & Concepts
NivolumabMedicineRenal cell carcinomaConcomitantInternal medicineAdverse effectNephrectomyOncologyGastroenterologyCancerImmunotherapyKidneyCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentFerroptosis and cancer prognosis